Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat

@article{Martel2000PreventionOB,
  title={Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat},
  author={C. Martel and S. Picard and Virgile Richard and A. Bélanger and C. Labrie and F. Labrie},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2000},
  volume={74},
  pages={45-56}
}
Some undesirable effects are associated with chronic estrogen and progestin administration used to prevent bone loss in postmenopausal women, thus leading to poor compliance and the need for improved therapeutic and preventive agents. We have thus studied the ability of the new antiestrogen EM-800 (SCH 57050) to prevent bone loss and lower serum cholesterol levels and compared its effects with those of raloxifene. Ovariectomized (OVX) female rats were treated by oral gavage for 37 weeks with… Expand
Bone Density and Morphology of Mammary Glands of Ovariectomized Rats Treated with Combined Raloxifene and Alendronate
TLDR
Evidence is provided to support the benefit of combined antiresorptive drugs, raloxifene and alendronate, on the bone without increasing risk to develop disease of the mammary glands. Expand
Effects of raloxifene and estradiol on bone turnover parameters in intact and ovariectomized rats
TLDR
It is suggested that RLX exerts its protective effects by reducing bone resorption, similar to that of estradiol, in ovx rats. Expand
Effects of Antiresorptive Drugs on Long Bone Growth, Body Weight Gain, and Serum Lipid Levels in Young Adult Ovariectomized Rats
TLDR
It is suggested that in young adult females who are subjected to estrogen deprivation, CEE or alendronate may be effective in preventing the bone from deterioration, however, their adverse events should be taken into account in the long-term use. Expand
In vitro anti-resorptive activity and prevention of ovariectomy-induced osteoporosis in female Sprague–Dawley rats by ormeloxifene, a selective estrogen receptor modulator
TLDR
Findings suggest potential of ormeloxifene in management of post-menopausal osteoporosis and beneficial effect on BMD in women taking this SERM for contraception or any hormone-related clinical disorder. Expand
Prospective evaluation of Vitamin K2, Raloxifene and their co-administration in osteoporotic rats.
TLDR
Vitamin K2 treated groups (either in single or combined with Raloxifene) had considerable biomechanical performance and reproductive tissue profile indicating that this agent is prospectively effective in osteoporosis management. Expand
The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.
TLDR
The positive results of EXE on bone and lipid metabolism in the OVX rat model merit further investigation of the effects of exemestane in postmenopausal women. Expand
Biomechanical and histological outcome of combined raloxifene-estrogen therapy on skeletal and reproductive tissues.
TLDR
Overall, combined therapy might be useful to minimize the individual side effects of raloxifene and estrogen on the uterus and still provide bone strength and toughness. Expand
The selective estrogen receptor modulator SCH 57068 prevents bone loss, reduces serum cholesterol and blocks estrogen-induced uterine hypertrophy in ovariectomized rats
TLDR
Hormone replacement therapy E(2) + SCH 57068 could be combined for the treatment and prevention of breast cancer or as a novel hormone replacement therapy in ovariectomized rats because of the potential for synergistic effects on bone, lipids and uteri. Expand
Combination treatment with eldecalcitol (ED-71) and raloxifene improves bone mechanical strength by suppressing bone turnover and increasing bone mineral density in ovariectomized rats.
TLDR
The results indicated that the combination treatment with ELD and RAL might be a beneficial therapy with respect to their combined effects of enhancing the mechanical properties of trabecular and cortical bone by suppressing bone turnover and increasing BMD more than either monotherapy. Expand
Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized Rats
TLDR
EXE and 17-H-EXE significantly prevent bone loss, enhance bone mechanical strength, and lower serum cholesterol and low-density lipoprotein levels in OVX rats, and these protective effects on end-organ function are not seen with the nonsteroidal inhibitor LET. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
TLDR
Raloxifene has promise as an agent with beneficial bone and cardiovascular effects in the absence of significant uterine effects, and ethynyl estradiol diverged dramatically from estrogen in its lack of significant estrogenic effects on uterine tissue. Expand
Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats
  • M. Sato, M. Rippy, H. Bryant
  • Biology, Medicine
  • FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • 1996
TLDR
Data point to advantages of Separate compounds in the management of bone, uterine, serum cholesterol, and adipose tissues after estrogen deficiency, and show that the benzothiophene raloxifene has potentially important advantages over estrogen, tamoxifen, or nafoxidine in the uterus. Expand
Estrogen treatment prevents osteopenia and depresses bone turnover in ovariectomized rats.
TLDR
It is indicated that estrogen treatment provides complete protection against osteopenia in OVX rats and the protective mechanism involves estrogenic suppression of bone turnover, consistent with the skeletal effects of estrogen therapy in postmenopausal women. Expand
Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia.
TLDR
Evidence is provided that raloxifene is a much more potent estrogen agonist on the skeleton and liver than on the uterus, and that estrogen treatment after menopause reduces body weight and serum cholesterol. Expand
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
TLDR
Daily therapy with raloxifene increases bone mineral density, lowers serum concentrations of total and low-density lipoprotein cholesterol, and does not stimulate the endometrium. Expand
Activity of raloxifene in immature and ovariectomized rat uterotrophic assays.
TLDR
It is confirmed that raloxifene exerts a genuine trophic effect on the rat uterus, and as a consequence, the uterotrophic assay can be relied upon to detect estrogens with only a marginal effect onThe uterus. Expand
Predominant androgenic component in the stimulatory effect of dehydroepiandrosterone on bone mineral density in the rat.
TLDR
The present data indicate that the potent stimulatory effect of DHEA on bone in the rat is mainly due to the local formation of androgens in bone cells and their intracrine action in osteoblasts. Expand
A controlled trial of raloxifene (LY139481) HCl: Impact on bone turnover and serum lipid profile in healthy postmenopausal women
TLDR
Study results indicate that raloxifene may provide beneficial effects to bone and serum lipids in humans without uterine stimulatory effects. Expand
Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women.
TLDR
The data strongly support the major importance of E deficiency for early postmenopausal bone loss, which is prevented by even a small substitution dose of E. Expand
A comparative study of the actions of tamoxifen, estrogen and progesterone in the ovariectomized rat.
TLDR
The findings indicate that in estrogen deficiency, tamoxifen has a weak estrogen agonist action on bone, and in the presence of estrogen it has anti-estrogen actions, with the dose level and mode of administration employed. Expand
...
1
2
3
4
5
...